ArticleJournal of patient-reported outcomes2022
Comparison of the EQ-5D-Y-5L, EQ-5D-Y-3L and PedsQL in children and adolescents.
Article in Journal of patient-reported outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Measurement Properties of the EQ-5D Instruments in Children and Adolescents: A Systematic Review.Applied health economics and health policy · 2025Pooled it
- Health-related quality of life in children and adolescents with paediatric acquired brain injury: Secondary data analysis from a randomised controlled trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Trial
- Health-related quality of life and adverse events during 14 days after receiving a live-attenuated influenza vaccine in Japanese children 4-15 years of age.Human vaccines & immunotherapeutics · 2026Article
- Responsiveness of the EQ-5D-Y-5L Parent-Proxy Version Among Children with Juvenile Idiopathic Arthritis.The patient · 2026Article
- Measuring and Valuing Health Using EuroQol Instruments: New Developments 2025 and Beyond.Applied health economics and health policy · 2025Review
- Comparing the measurement properties of the EQ-5D-Y-3L, EQ-5D-Y-5L and CHU9D in children and adolescents: a measurement property study.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Psychometric validation of the Chinese versions of EQ-5D-Y-3L and the experimental EQ-TIPS in children and adolescents with COVID-19.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- A head-to-head comparison of the adult EQ-5D-5L and youth EQ-5D-Y-5L in adolescents with idiopathic scoliosis.Journal of patient-reported outcomes · 2025Article
- Article
- Performance of the Experimental EuroQol Toddler and Infant Populations (EQ-TIPS) and PedsQL in Infants and Toddlers with a Health Condition.Journal of health economics and outcomes research · 2025Article
- Validity and responsiveness of EQ-5D-Y in children with haematological malignancies and their caregivers.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data.PharmacoEconomics · 2024Article
- Core outcome measurement set for research and clinical practice in post-COVID-19 condition (long COVID) in children and young people: an international Delphi consensus study "PC-COS Children".The European respiratory journal · 2024Review
- Article
- Psychometric Evaluation of the PedsQL GCS and CHU9D in Australian Children and Adolescents with Common Chronic Health Conditions.Applied health economics and health policy · 2023Article
- Comparisons of EQ-5D-Y and PedsQL in pediatric patients with mild-to-moderate chronic kidney disease in longitudinal analyses.Health and quality of life outcomes · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThere is an increased use of Patient-Reported Outcome Measures (PROMs) in children and adolescents. The aim of this study was to compare the feasibility, concurrent validity and known-group validity of the EQ-5D-Y-3L (Y-3L), EQ-5D-Y-5L (Y-5L) and PedsQL self-report PROMs.
methodsFive hundred and fifty children and adolescents, aged 8-15-years, with acute and chronic health conditions and a general population sample were recruited from schools and hospitals in Cape Town South Africa. All respondents self-completed the Y-5L, PedsQL, Self-Rated Health Question and Y-3L. Feasibility of the measures was determined by comparing the number of missing responses. Convergent validity was assessed by Spearman's and Intra-class correlations on the corresponding items and summary scores respectively. Known-groups validity across health conditions was assessed across the summary scores of the measures with analysis of variance (ANOVA).
resultsThe Y-3L and Y-5L had a total of 1% and 3.5% missing responses compared to 19% on the PedsQL. Similar items on the PedsQL and Y-3L/Y-5L showed high correlations (> 0.5) and related items showed moderate correlations (0.3). PedsQL total score was moderately and significantly associated with Y-3L and Y-5L level sum and VAS scores. The Y-3L and Y-5L level sum and VAS scores showed significant differences between known health groups whereas the PedsQL only showed differences between those with acute and chronic illness.
conclusionThe results of this study show that the Y-3L and Y-5L showed comparable psychometric validity to the PedsQL. When considering the choice between the PedsQL, Y-5L and Y-3L these study results indicate that the EQ-5D-Y instruments (Y-3L and Y-5L) are recommended for studies assessing known-group validity or where missing data should be minimised. The PedsQL generic measure may be preferable in future studies including the general population where a ceiling effect is anticipated. When considering the choice between the Y-5L and the Y-3L there was no systematic difference in the validity between these instruments or between the Y-3L or Y-5L and the PedsQL. Thus, the selection of EQ-5D-Y measures to include in future studies should be guided by the characteristics of the population to be tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.